Genezen to license CSL’s lentiviral vector production system

21 Feb 2024
www.pharmaceutical-technology.com
License out/inGene TherapyClinical StudyCell Therapy
Genezen to license CSL’s lentiviral vector production system
Preview
Source: Pharmaceutical Technology
Cytegrity technology will aid in cost-effective lentiviral vector production for gene and cell therapies. Credit: Akimov Igor / Shutterstock.com.
Genezen to license CSL’s lentiviral vector production system
Preview
Source: Pharmaceutical Technology
Contract development and manufacturing organisation (CDMO) Genezen has announced plans to license CSL’s Cytegrity stable lentivirus production system.
The advanced inducible technology produces lentiviral vectors (LVVs), which are vital for gene and cell therapies.
The Cytegrity technology enables scalable and cost-efficient production of LVVs at clinically efficient titers.
It has shown promising safety and efficacy results and is validated through early clinical testing.
LVVs are generally manufactured on a small scale leveraging plasmid-based transient transfection technology.
See Also:SG-2501 by Hangzhou Sumgen Biotech for Primary Systemic Amyloidosis: Likelihood of Approval
Genezen to license CSL’s lentiviral vector production system
Preview
Source: Pharmaceutical Technology
Genezen to license CSL’s lentiviral vector production system
Preview
Source: Pharmaceutical Technology
The Cytegrity system represents a significant advancement and is one of the first to facilitate continuous manufacturing from a stably transfected adherent or suspension cell line.
This innovation alleviates the requirement for expensive plasmid inputs, reduces the complexity of the process and enables large-scale batch manufacturing.
It also offers the potential for multiple harvests and reduced batch-to-batch variability to cut down production expenditures for Genezen’s clients.
Genezen’s licensing of the Cytegrity system marks a substantial investment in next-generation technology for LVV production.
The strategic move will provide its clients with immediate access to pioneering technology for stable and scalable high-titer clinical lentivirus production.
The company is ready to provide the Cytegrity technology to its customers at its good manufacturing practice (GMP) facility in Fishers, Indiana, US.
Genezen president and CEO Steve Favaloro said: “We have significant, hands-on experience scaling up and producing LVV using this stable production system at our GMP vector facility in Fishers, Indiana.
“Stable producer cell lines can be developed for clients in under four months, and this system will help alleviate the current global viral vector shortage by providing customers with a scalable, high-quality vector platform.
“This licensing capability is a significant value-add for our current and future LVV customers, and furthers our collective mission to bring gene and cell therapies more efficiently to patients.”
Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
Free WhitepaperCell and gene therapies: Pipe dream to pipeline
The cell and gene industry is gaining momentum, with a new wave of therapies promising to transform the way doctors treat, and even cure, disease. In this report, Cytiva and GlobalData have collaborated to explore the rise of the cell and gene therapy industries, the current state of the market, present and future opportunities for advancement, and the challenges that lie ahead.
Genezen to license CSL’s lentiviral vector production system
Preview
Source: Pharmaceutical Technology
-->
By downloading this case study, you acknowledge that GlobalData may share your information with Cytiva Thematic and that your personal data will be used as described in their Privacy Policy
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.